We are live on ! Find out more
GRCL

Gracell Biotechnologies Inc. American Depositary Shares

Delisted

GRCL was delisted on the 21st of February, 2024.

63 hedge funds and large institutions have $552M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

311% more capital invested

Capital invested by funds: $134M → $552M (+$418M)

238% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 8

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

40% more funds holding

Funds holding: 4563 (+18)

64% less call options, than puts

Call options by funds: $216K | Put options by funds: $602K

Holders
63
Holders Change
+18
Holders Change %
+40%
% of All Funds
0%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0%
New
27
Increased
20
Reduced
10
Closed
8
Calls
$216K
Puts
$602K
Net Calls
-$386K
Net Calls Change
-$386K

GRCL Hedge Fund Activity: Q4 2023 in Review

63 institutional investors reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q4 2023, worth a combined $552M — up 311% from $134M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new GRCL positions and 8 closed out — a net gain of 19 holders — while 20 added to existing stakes and 10 trimmed.

The largest buyer was Sio Capital Management, adding an estimated $13.3M. The largest seller was Hudson Bay Capital Management, cutting an estimated $7.87M.

  • 63 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q4 2023, up from 45 in Q3 2023.
  • Funds reported $552M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q4 2023, up 311% quarter-over-quarter.
  • 27 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q4 2023 and 8 closed out, a net change of +19 holders.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q4 2023 was Sio Capital Management, an estimated $13.3M added.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q4 2023 was Hudson Bay Capital Management, an estimated $7.87M sold.

Based on aggregated 13F filings for Q4 2023.